Hervor Therapeutics
π¨π³China
- Country
- π¨π³China
- Ownership
- Private, Subsidiary
- Established
- 2021-04-26
- Employees
- -
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Phase 1
2 (100.0%)TIL for Patients With Advanced Solid Tumor
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hervor Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT06334783
- Locations
- π¨π³
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China
π¨π³Nanjing Jinling Hospital, Nanjing, Jiangsu, China
π¨π³Wowen's hospital, School of medicine, Zhejiang University, Hangzhou, Zhejiang, China
HV-101 for Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hervor Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05868915
- Locations
- π¨π³
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
News
No news found